Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bausch Health Companies Inc. (BHC)

Bausch Health director Michael Goettler resigns to become Knoa Pharma CEO

Neutral Impact 2 of 5 leadership Written later

Michael Goettler resigned from the Bausch Health Board of Directors, effective June 30, 2026, to take up the role of President and Chief Executive Officer of Knoa Pharma LLC. The company said his resignation did not result from any disagreement over its operations, policies or practices. The filing contains no financial figures, and the change affects board composition only.

Key points

  • Goettler notified the company of his resignation on June 26, 2026; it takes effect June 30, 2026.
  • He is joining Knoa Pharma LLC as President and Chief Executive Officer.
  • The company states the resignation was not due to any disagreement on its operations, policies or practices.
  • Board Chairperson John A. Paulson thanked Goettler for his service in the July 1, 2026 press release.

The filing

CompanyBausch Health Companies Inc. (BHC)
Form8-K, current report
Filed with the SECJul 1, 2026, 4:23 PM ET
Accession number0000885590-26-000089

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.